Investigation of the ototoxicity of gadoteridol (ProHance) and gadodiamide (Omniscan) in mice.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 0370354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-2251 (Electronic) Linking ISSN: 00016489 NLM ISO Abbreviation: Acta Otolaryngol Subsets: MEDLINE

Publication: 2015- : Abingdon, Oxford : Taylor & Francis
Original Publication: Stockholm : Scandinavian University Press

Cochlea/*drug effects ; Contrast Media/*toxicity ; Gadolinium DTPA/*toxicity ; Heterocyclic Compounds/*toxicity ; Organometallic Compounds/*toxicity; Animals ; Evoked Potentials, Auditory, Brain Stem ; Gadolinium/toxicity ; Male ; Mice, Inbred C57BL ; Random Allocation

Conclusion: In the mouse, when a tympanic perforation is present, gadoteridol does not seem to cause ototoxicity. Gadodiamide may cause mild ototoxicity other than toxicity to the outer hair cells of the cochlea.
Objectives: Endolymphatic hydrops have been visualized through intra-tympanic injection of gadolinium-based contrast agents (GBCAs) and three-dimensional fluid-attenuated inversion recovery (3-D FLAIR) magnetic resonance imaging. However, reports on the safety of GBCAs are limited. This study aimed to assess ototoxicity of gadoteridol and gadodiamide.
Method: In a prospective, randomized, controlled trial, myringotomies in the left ear were performed in 20 male C57 BL/6 mice. After testing the baseline auditory brainstem response (ABR) (range = 8-32 kHz), the test solution (gadoteridol, gadodiamide, saline, or cisplatin) was injected into the left ear. ABR testing was repeated 14 days after test solution application. In morphological experiments, images of post-mortem surface preparations were assessed for cochlear hair cell status.
Results: At 14 days following gadoteridol application, there was no significant change in ABR thresholds at 8, 16, or 32 kHz. Gadodiamide application caused a significant change in the ABR threshold at 8 kHz. Apparent cochlear hair cell loss was not observed in the surface preparation after gadoteridol or gadodiamide application.

Keywords: Auditory brainstem response; MRI; gadodiamide; gadolinium-based contrast agent; gadoteridol; mouse; ototoxicity; surface preparation

0 (Contrast Media)
0 (Heterocyclic Compounds)
0 (Organometallic Compounds)
0199MV609F (gadoteridol)
84F6U3J2R6 (gadodiamide)
AU0V1LM3JT (Gadolinium)
K2I13DR72L (Gadolinium DTPA)

Date Created: 20160618 Date Completed: 20170209 Latest Revision: 20170209

20250114

10.1080/00016489.2016.1193892

27315460